Ovid Therapeutics Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Ovid Therapeutics Inc. (OVID) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $1.43 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-13
- Ovid Therapeutics Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $1.43M, a 17.39% increase year-over-year.
- Ovid Therapeutics Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $1.05M, a 18.54% decline year-over-year.
- Ovid Therapeutics Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $1.11M, a 15.15% decline year-over-year.
- Ovid Therapeutics Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $1.22M, a 29.94% decline year-over-year.
- Ovid Therapeutics Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $4.81M, a 23.41% decline from fiscal 2024.
- Ovid Therapeutics Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $6.28M, a 13.85% decline from fiscal 2023.
- Ovid Therapeutics Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $7.29M, a 11.11% increase from fiscal 2022.
- Ovid Therapeutics Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $6.56M, a 29.72% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month as first filed | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1.43M 10-Q · filed 2026-08-13 | $2.48M derived: sum of 2 quarters · filed 2026-08-13 | ||||
| 2026-03-31 | $1.05M 10-Q · filed 2026-08-13 | |||||
| 2025-12-31 | $4.81M 10-K · filed 2026-03-18 | |||||
| 2025-09-30 | $1.11M 10-Q · filed 2025-11-12 | $2.33M derived: sum of 2 quarters · filed 2026-08-13 | $3.61M derived: sum of 3 quarters · filed 2026-08-13 | |||
| 2025-06-30 | $1.22M 10-Q · filed 2026-08-13 | $2.50M derived: sum of 2 quarters · filed 2026-08-13 | ||||
| 2025-03-31 | $1.28M 10-Q · filed 2026-08-13 | |||||
| 2024-12-31 | $6.28M 10-K · filed 2026-03-18 | |||||
| 2024-09-30 | $1.31M 10-Q · filed 2025-11-12 | $3.05M derived: sum of 2 quarters · filed 2025-11-12 | $5.01M derived: sum of 3 quarters · filed 2025-11-12 | |||
| 2024-06-30 | $1.74M 10-Q · filed 2025-11-12 | $3.71M derived: sum of 2 quarters · filed 2025-11-12 | ||||
| 2024-03-31 | $1.97M 10-Q · filed 2025-11-12 | |||||
| 2023-12-31 | $7.29M 10-K · filed 2025-03-11 | $7.29M 10-K · filed 2024-03-08 | ||||
| 2023-09-30 | $1.63M 10-Q · filed 2024-11-12 | $1.63M 10-Q · filed 2023-11-03 | $3.58M derived: sum of 2 quarters · filed 2024-11-12 | $5.50M derived: sum of 3 quarters · filed 2024-11-12 | ||
| 2023-06-30 | $1.95M 10-Q · filed 2024-11-12 | $1.95M 10-Q · filed 2023-08-04 | $3.87M derived: sum of 2 quarters · filed 2024-11-12 | |||
| 2023-03-31 | $1.92M 10-Q · filed 2024-11-12 | $1.92M 10-Q · filed 2023-05-05 | ||||
| 2022-12-31 | $6.56M 10-K · filed 2024-03-08 | |||||
| 2022-09-30 | $1.78M 10-Q · filed 2023-11-03 | $3.50M derived: sum of 2 quarters · filed 2023-11-03 | $4.83M derived: sum of 3 quarters · filed 2023-11-03 | |||
| 2022-06-30 | $1.72M 10-Q · filed 2023-11-03 | $3.05M derived: sum of 2 quarters · filed 2023-11-03 | ||||
| 2022-03-31 | $1.32M 10-Q · filed 2023-11-03 | |||||
| 2021-12-31 | $5.05M 10-K · filed 2023-03-13 | |||||
| 2021-09-30 | $1.16M 10-Q · filed 2022-11-08 | $2.42M derived: sum of 2 quarters · filed 2022-11-08 | $3.74M derived: sum of 3 quarters · filed 2022-11-08 | |||
| 2021-06-30 | $1.26M 10-Q · filed 2022-11-08 | $2.58M derived: sum of 2 quarters · filed 2022-11-08 | ||||
| 2021-03-31 | $1.32M 10-Q · filed 2022-11-08 | |||||
| 2020-12-31 | $7.53M 10-K · filed 2022-03-15 | |||||
| 2020-09-30 | $2.62M 10-Q · filed 2021-11-10 | $4.17M derived: sum of 2 quarters · filed 2021-11-10 | $5.47M derived: sum of 3 quarters · filed 2021-11-10 | |||
| 2020-06-30 | $1.56M 10-Q · filed 2021-11-10 | $2.86M derived: sum of 2 quarters · filed 2021-11-10 | ||||
| 2020-03-31 | $1.30M 10-Q · filed 2021-11-10 | |||||
| 2019-12-31 | $5.21M 10-K · filed 2021-03-15 | |||||
| 2019-09-30 | $1.18M 10-Q · filed 2020-11-13 | $2.44M derived: sum of 2 quarters · filed 2020-11-13 | $4.08M derived: sum of 3 quarters · filed 2020-11-13 | |||
| 2019-06-30 | $1.25M 10-Q · filed 2020-11-13 | $2.89M derived: sum of 2 quarters · filed 2020-11-13 | ||||
| 2019-03-31 | $1.64M 10-Q · filed 2020-11-13 | |||||
| 2018-12-31 | $7.06M 10-K · filed 2020-03-11 | |||||
| 2018-09-30 | $1.69M 10-Q · filed 2019-11-08 | $3.54M derived: sum of 2 quarters · filed 2019-11-08 | $5.33M derived: sum of 3 quarters · filed 2019-11-08 | $6.74M derived: sum of 4 quarters · filed 2019-11-08 | ||
| 2018-06-30 | $1.84M 10-Q · filed 2019-11-08 | $3.64M derived: sum of 2 quarters · filed 2019-11-08 | $5.05M derived: sum of 3 quarters · filed 2019-11-08 | $6.43M derived: sum of 4 quarters · filed 2019-11-08 | ||
| 2018-03-31 | $1.79M 10-Q · filed 2019-11-08 | $3.21M derived: sum of 2 quarters · filed 2019-11-08 | $4.58M derived: sum of 3 quarters · filed 2019-11-08 | $6.77M derived: sum of 4 quarters · filed 2019-11-08 | ||
| 2017-12-31 | $1.41M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | $2.79M derived: sum of 2 quarters · filed 2019-03-07 | $4.98M derived: sum of 3 quarters · filed 2019-03-07 | $6.40M 10-K · filed 2019-03-07 | ||
| 2017-09-30 | $1.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $3.57M derived: sum of 2 quarters · filed 2017-11-09 | $4.99M 10-Q · filed 2017-11-09 | |||
| 2017-06-30 | $2.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-10 | $3.61M 10-Q · filed 2017-08-10 | ||||
| 2017-03-31 | $1.42M 10-Q · filed 2017-06-13 | |||||
| 2016-12-31 | $3.64M 10-K · filed 2018-03-29 | |||||
| 2015-12-31 | $1.46M 10-K · filed 2018-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |